Upregulation of FGFR3 and HIF-1α expression in muscle invasive bladder cancer

  • Syah Mirsya Warli Department of Urology, Faculty of Medicine, Universitas Sumatera Utara, H. Adam Malik Hospital, Medan
  • Lidya Imelda Laksmi Department of Pathology, Faculty of Medicine, Universitas Sumatera Utara, H. Adam Malik Hospital, Medan
  • Ferry Safriadi Department of Urology, Faculty of Medicine, Universitas Padjajaran, Hasan Sadikin Hospital, Bandung
  • Rainy Umbas Department of Urology, Faculty of Medicine, Univesitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta
Keywords: bladder cancer, fibroblast growth factor receptor-3, predictive factors, hypoxia-inducible factor-1α
Abstract viewed: 913 times
PDF downloaded: 844 times
HTML downloaded: 97 times
EPUB downloaded: 213 times


BACKGROUND The major risks in patients diagnosed with non-muscle invasive bladder cancer (NMIBC)are recurrence, progression of muscle invasive bladder cancer (MIBC), and metastasis. Biological markers such as fibroblast growth factor receptor-3 (FGFR3) and hypoxia-inducible factor-1α (HIF-1α) are related to muscle invasiveness of bladder cancer. This study was aimed to analyze the expression of FGFR3 and HIF-1α to predict muscle invasiveness in bladder cancer patients.

METHODS This was an observational study with a case-control design. Sixty patients with bladder cancer, who underwent histopathology examinations at the Department of Pathology, Faculty of Medicine, Universitas Sumatera Utara/H. Adam Malik Hospital from January 2012 to December 2015, were included in this study. Samples were then classified into 30 NMIBC and 30 MIBC groups. All samples were analyzed with an immunohistochemistry assay for FGFR3 and HIF-1α. H-scores were used to determine the relationships between each group.

RESULTS FGFR3 was expressed in 29 (96.7%) patients of the NMIBC group, and 23 (76.7%) patients of the MIBC group (p=0.026, OR=8.8; 95% CI=1.01–76.96). HIF-1α was expressed in only 1 (3.33%) patient of the NMIBC group, and 15 (50%) patients of the MIBC group (p<0.001, OR=29; 95% CI=3.49–241.13).

CONCLUSIONS There was a difference in upregulation of FGFR3 and HIF-1α expression in both the NMIBC and MIBC groups.


Download data is not yet available.


  1. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92. https://doi.org/10.1016/j.eururo.2013.11.046

  2. Sariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol. 2008;54(1):41–53. https://doi.org/10.1016/j.eururo.2008.01.004

  3. Ceng L, Zhang S, Davidson DD, MacLennan GT, Koch MO, Montironi R, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 2009;5(6):843–57. https://doi.org/10.2217/fon.09.50

  4. Masushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol. 2011;18(9):616–29. https://doi.org/10.1111/j.1442-2042.2011.02809.x

  5. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238–53. https://doi.org/10.1016/j.eururo.2015.01.032

  6. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41. https://doi.org/10.1038/nrc3817

  7. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, et al. Summary and recommendations from the National Cancer Institute’s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer. 2016;2(2):165–202. https://doi.org/10.3233/BLC-160053

  8. Deniz H, Karakök M, Yagci F, Güldür ME. Evaluation of relationship between HIF-1 alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol. 2010;42(1):103–7. https://doi.org/10.1007/s11255-009-9590-5

  9. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46(8 Suppl):4244s–8s.

  10. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21(10):1912–21. https://doi.org/10.1200/JCO.2003.05.073

  11. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25(18):2685–96. https://doi.org/10.1038/sj.onc.1209249

  12. Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, et al. Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol. 2008;29(5):311–22. https://doi.org/10.1159/000170878

  13. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012;2012:429213. https://doi.org/10.1155/2012/429213

  14. Dodurga Y, Tataroglu C, Kesen Z, Satiroglu-Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10(1):86–95. https://doi.org/10.4238/vol10-1gmr923

  15. Babaian A, Kariakin OB, Teplov AA, Zaletaev DV, Nemtsova MV. Some molecular-genetic markers, defining the pathogenesis of superficial and invasive bladder cancer. Mol Biol (Mosk). 2011;45(6):1012–6. https://doi.org/10.1134/S0026893311060021

  16. Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010;34(6):724–32. https://doi.org/10.1016/j.canep.2010.05.003

  17. Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa FM, et al. Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. Br J Cancer. 2013;109(1):50–9. https://doi.org/10.1038/bjc.2013.240

  18. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56.e25. https://doi.org/10.1016/j.cell.2017.09.007

  19. Hunter BA, Eustace A, Irlam JJ, Valentine HR, Denley H, Oguejiofor KK. et al. Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer. Br J Cancer. 2014;111(3):437–43. https://doi.org/10.1038/bjc.2014.315

  20. omlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 2007;213(1):91–8. https://doi.org/10.1002/path.2207

How to Cite
Warli SM, Laksmi LI, Safriadi F, Umbas R. Upregulation of FGFR3 and HIF-1α expression in muscle invasive bladder cancer. Med J Indones [Internet]. 2019May8 [cited 2024Jul.16];28(1):3-. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2396
Basic Medical Research